Asian Market Value Stock Picks For Estimated Undervaluation
Name
Current Price
Fair Value (Est)
Discount (Est)
PixArt Imaging (TPEX:3227)
NT$221.50
NT$439.89
49.6%
Ficont Industry (Beijing) (SHSE:605305)
CN¥26.49
CN¥52.54
49.6%
Shenzhen KSTAR Science and Technology (SZSE:002518)
CN¥22.82
CN¥44.80
49.1%
People & Technology (KOSDAQ:A137400)
₩37700.00
₩73423.22
48.7%
Shenzhen Yinghe Technology (SZSE:300457)
CN¥17.60
CN¥34.34
48.7%
Dive (TSE:151A)
¥931.00
¥1852.82
49.8%
Heartland Group Holdings (NZSE:HGH)
NZ$0.84
NZ$1.64
48.9%
BalnibarbiLtd (TSE:3418)
¥1163.00
¥2317.93
49.8%
Wenzhou Yihua Connector (SZSE:002897)
CN¥39.84
CN¥77.92
48.9%
HanJung Natural Connectivity System.co.Ltd (KOSDAQ:A107640)
₩28000.00
₩55868.52
49.9%
Click here to see the full list of 289 stocks from our Undervalued Asian Stocks Based On Cash Flows screener.
Here's a peek at a few of the choices from the screener.
Overview: SAMG Entertainment Co., Ltd. is involved in the production of TV series, animated feature films, advertisements, and games globally, with a market cap of ₩503.71 billion.
Operations: The company's revenue is primarily derived from its computer graphics segment, generating ₩116.44 million.
Estimated Discount To Fair Value: 12.2%
SAMG Entertainment is trading at ₩62,000, 12.2% below its estimated fair value of ₩70,576.52, indicating potential undervaluation based on cash flows. Despite recent share price volatility and revenue growth of 22.4% last year, it's expected to become profitable within three years with earnings projected to grow significantly at 107.85% annually. The company's forecasted return on equity is high at 34.4%, suggesting strong future financial performance relative to benchmarks.
Our expertly prepared growth report on SAMG Entertainment implies its future financial outlook may be stronger than recent results.
Take a closer look at SAMG Entertainment's balance sheet health here in our report.
Overview: Tokai Carbon Co., Ltd. is a Japanese company that manufactures and sells carbon-related products and services, with a market cap of ¥210.99 billion.
Operations: The company's revenue segments include Fine Carbon at ¥54.09 billion, Graphite Electrodes at ¥49.07 billion, Smelting and Lining at ¥64.79 billion, Carbon Black Business at ¥156.82 billion, and Industrial Furnaces and Related Products at ¥16.96 billion.
Estimated Discount To Fair Value: 18.6%
Tokai Carbon, trading at ¥988.4, is priced 18.6% below its estimated fair value of ¥1,214.36, reflecting potential undervaluation based on cash flows. Despite a low forecasted return on equity of 7.8% in three years and slower revenue growth at 4.9% annually compared to the market average, it is expected to achieve profitability within the same timeframe with above-average profit growth projections and a dividend yield of 3.04%.
Upon reviewing our latest growth report, Tokai Carbon's projected financial performance appears quite optimistic.
Click here and access our complete balance sheet health report to understand the dynamics of Tokai Carbon.
Overview: Evergreen Aviation Technologies Corporation offers aircraft maintenance services to airline partners both in Taiwan and internationally, with a market cap of NT$42.89 billion.
Operations: The company generates revenue primarily through its aircraft maintenance services provided to airline partners in Taiwan and abroad.
Estimated Discount To Fair Value: 43.1%
Evergreen Aviation Technologies, trading at NT$114.5, is significantly undervalued compared to its estimated fair value of NT$201.3. The company's earnings are expected to grow substantially at 24.31% annually, outpacing the Taiwan market's average growth rate. Despite this growth potential, its dividend yield of 3.93% is not well supported by earnings or free cash flows. Recent quarterly results showed increased sales and net income year-over-year, highlighting positive operational performance trends.
In light of our recent growth report, it seems possible that Evergreen Aviation Technologies' financial performance will exceed current levels.
Navigate through the intricacies of Evergreen Aviation Technologies with our comprehensive financial health report here.
Get an in-depth perspective on all 289 Undervalued Asian Stocks Based On Cash Flows by using our screener here.
Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
Unlock the power of informed investing with Simply Wall St, your free guide to navigating stock markets worldwide.
Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include KOSDAQ:A419530 TSE:5301 and TWSE:2645.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@simplywallst.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Asian Growth Stocks With Insider Ownership Expecting Up To 93% Earnings Growth
As Asian markets experience a period of growth, bolstered by strong corporate earnings and resilient economic indicators, investors are increasingly focusing on companies with robust insider ownership. In this environment, stocks that combine high insider stakes with significant expected earnings growth can present compelling opportunities for those seeking to align their interests with company insiders who have a vested interest in the firm's success. Top 10 Growth Companies With High Insider Ownership In Asia Name Insider Ownership Earnings Growth Vuno (KOSDAQ:A338220) 15.6% 109.8% Techwing (KOSDAQ:A089030) 19.1% 68% Suzhou Sunmun Technology (SZSE:300522) 35.4% 77.7% Sineng ElectricLtd (SZSE:300827) 36% 25.8% Shanghai Huace Navigation Technology (SZSE:300627) 24.3% 24.3% Novoray (SHSE:688300) 23.6% 28.2% M31 Technology (TPEX:6643) 30.8% 95.5% Laopu Gold (SEHK:6181) 35.5% 43% Gold Circuit Electronics (TWSE:2368) 31.4% 32.8% Fulin Precision (SZSE:300432) 12.8% 43.7% Click here to see the full list of 593 stocks from our Fast Growing Asian Companies With High Insider Ownership screener. Let's explore several standout options from the results in the screener. RemeGen Simply Wall St Growth Rating: ★★★★★★ Overview: RemeGen Co., Ltd. is a biopharmaceutical company focused on discovering, developing, and commercializing biologics for autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States with a market cap of approximately HK$40.14 billion. Operations: RemeGen's revenue from biopharmaceutical research, service, production, and sales amounts to approximately CN¥1.91 billion. Insider Ownership: 11.2% Earnings Growth Forecast: 66.3% p.a. RemeGen is experiencing significant growth, with earnings forecasted to grow 66.34% annually and revenue expected to increase by 24.6% per year, outpacing the Hong Kong market. Despite high share price volatility, it trades at a notable discount below its estimated fair value. Recent developments include FDA clearance for clinical trials of RC148 in the US and a global Phase 3 trial for Telitacicept, highlighting its innovative drug pipeline and potential for future expansion in international markets. Unlock comprehensive insights into our analysis of RemeGen stock in this growth report. Our comprehensive valuation report raises the possibility that RemeGen is priced higher than what may be justified by its financials. Anhui Estone Materials TechnologyLtd Simply Wall St Growth Rating: ★★★★★☆ Overview: Anhui Estone Materials Technology Co., Ltd specializes in lithium battery coating, electronic communication functional filling, and low-smoke halogen-free flame-retardant materials in China with a market cap of CN¥5.24 billion. Operations: The company generates revenue of CN¥510.72 million from its specialty chemicals segment. Insider Ownership: 32.8% Earnings Growth Forecast: 60.8% p.a. Anhui Estone Materials Technology Ltd. is projected to see robust expansion, with earnings anticipated to grow 60.8% annually and revenue expected to rise by 23.7% per year, surpassing the Chinese market's growth rates. The company recently turned profitable but faces challenges from large one-off items affecting its financial results. Despite these hurdles, no substantial insider trading activity has been reported in recent months, indicating stability in insider sentiment toward the company's prospects. Click here to discover the nuances of Anhui Estone Materials TechnologyLtd with our detailed analytical future growth report. Our valuation report unveils the possibility Anhui Estone Materials TechnologyLtd's shares may be trading at a premium. Caliway Biopharmaceuticals Simply Wall St Growth Rating: ★★★★★☆ Overview: Caliway Biopharmaceuticals Co., Ltd. and its subsidiaries focus on developing drugs for aesthetic medicine and chronic inflammation, with a market cap of NT$208.61 billion. Operations: Caliway Biopharmaceuticals Co., Ltd. generates revenue through its focus on drug development for aesthetic medicine and chronic inflammation. Insider Ownership: 24.2% Earnings Growth Forecast: 93.8% p.a. Caliway Biopharmaceuticals is experiencing significant growth potential, with revenue forecasted to grow at 89% annually, outpacing the Taiwanese market. The company recently gained recognition by being added to the MSCI Global Standard Index and has initiated pivotal Phase 3 trials for its innovative drug CBL-514. Despite a volatile share price and current lack of meaningful revenue, Caliway's strategic advancements in clinical development position it well for future profitability within three years. Delve into the full analysis future growth report here for a deeper understanding of Caliway Biopharmaceuticals. The valuation report we've compiled suggests that Caliway Biopharmaceuticals' current price could be inflated. Key Takeaways Get an in-depth perspective on all 593 Fast Growing Asian Companies With High Insider Ownership by using our screener here. Curious About Other Options? Trump has pledged to "unleash" American oil and gas and these 22 US stocks have developments that are poised to benefit. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years. Companies discussed in this article include SEHK:9995 SHSE:688733 and TWSE:6919. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
16 minutes ago
- San Francisco Chronicle
Asian shares are mixed after days of gains driven by hopes for US rate cuts
MANILA, Philippines (AP) — Asian shares were mixed on Thursday after days of gains driven by hopes for lower U.S. interest rates, while U.S. futures slipped. In Tokyo, the Nikkei 225 fell 1.4% to 42,657.94 as investors sold to lock in recent gains that have taken the benchmark to all-time records. The Japanese yen rose against the dollar after U.S. Treasury Secretary Scott Bessent said in an interview with Bloomberg that Japan was 'behind the curve' in monetary tightening. He was referring to the slow pace if increases in Japan's near-zero interest rates. Low interest rates tend to make the yen weaker against the dollar, giving Japanese exporters a cost advantage in overseas sales. The dollar fell to 146.55 Japanese yen early Thursday, down from 147.39 yen. The euro fell to $1.1703 from $1.1705. In Chinese markets, Hong Kong's Hang Seng index shed less than 0.1% to 25,597.85, while the Shanghai composite index gained 0.2% to 3,690.88. South Korea's Kospi slid 0.3% to 3,215.61, while Australia's S&P ASX 200 index added 0.5% to 8,871.80. Taiwan's TAIEX fell 0.4%, while India's Sensex edged 0.1% higher. 'Asian markets opened today like a party that ran out of champagne before midnight — the music still playing, but the dance floor thinning out,' Stephen Innes of SPI Asset Management said in a commentary. The futures for the S&P 500 and the Dow Jones Industrial Average were down less than 0.1%. On Wednesday, U.S. stocks ticked higher, extending a global rally fueled by hopes the Federal Reserve will cut U.S. interest rates. The S&P 500 rose 0.3% to 6,466.58, coming off its latest all-time high. The Dow climbed 1% to 44,922.27, while the Nasdaq composite added 0.1% to its own record set the day before, closing at 21,713.14. Treasury yields eased in the bond market in anticipation that the Fed will cut its main interest rate for the first time this year at its next meeting in September. Lower rates can boost investment prices and the economy by making it cheaper for U.S. households and businesses to borrow to buy houses, cars or equipment, though they risk worsening inflation. Stocks of companies on Wall Street that could benefit most from lower interest rates helped lead the way. PulteGroup climbed 5.4%, and Lennar rose 5.2% as part of a broad rally for homebuilders and others in the housing industry. Lower rates could make mortgages cheaper to get, which could spur more buying. The cryptocurrency exchange company Bullish ended its debut day of trading after an initial public offering of more than $10 billion with a gain of nearly 84% to $68 a share. The hopes for lower interest rates are helping to drown out criticism that the U.S. stock market has broadly grown too expensive after its big leap since hitting a low in April. President Donald Trump has angrily been calling for cuts to help the economy, often insulting the Fed Chair Jerome Powell while doing so. But the Fed has hesitated of the possibility that Trump's sweeping higher tariffs could make inflation much worse. Fed officials have said they want to see more fresh data about inflation before moving. On Thursday, a report will show how bad inflation was at the wholesale level across the United States. Economists expect it to show inflation accelerated a touch to 2.4% in July from 2.3% in June.
Bloomberg
an hour ago
- Bloomberg
China, India in Talks to Resume Border Trade After 5-Year Pause
India and China are discussing resuming border trade of locally made goods after more than five years, marking the latest step in a slow but steady effort by the Asian neighbors to ease long-standing tensions, according to officials in New Delhi familiar with the matter. Both sides have proposed restarting trade through designated points on the shared border, and the matter is currently under bilateral discussion, the people said, asking not to be identified as the discussions are still private.
